Friday, April 26, 2024
Advertisement
Updated on: April 21, 2021 16:40 IST

Bharat Biotech announces phase 3 results of COVAXIN

The whole virion inactivated COVID-19 vaccine candidate demonstrated an interim vaccine efficacy of 78% in its Phase 3 clinical trial.

Latest Videos

Advertisement
Advertisement
Advertisement
Advertisement